BioPharmSignal logoBioPharmSignal

Biotech News

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Rocket Pharmaceuticals (RCKT)Rocket PharmaceuticalsFDA / regulatory

Prescription Drug User Fee Act (PDUFA) target action date is March 28, 2026 All primary and secondary endpoints were met, and KRESLADI™ was well tolerated Rocket is eligible for a Rare Pediatric Disease Priority Review Voucher, should KRESLADI ™ be approved CRANBURY, N.J. --(BUSINESS WIRE)--Oct.

Related news

RCKTRocket Pharmaceuticals2026-09-15 11:00 EST

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

PHVSPharvaris2026-07-06 10:50 EST

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

CAPRCapricor Therapeutics2026-06-26 14:02 EST

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

NTLAIntellia2026-09-08 12:00 EST

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)

SRPTSarepta Therapeutics2026-06-30 12:30 EST

Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®

MNPRMonopar2026-06-30 12:00 EST

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease

ARWRArrowhead Pharmaceuticals2026-08-04 20:00 EST

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

KPTIKaryopharm Therapeutics2026-08-31 11:30 EST

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

GSKGSK plc2026-08-24 07:01 EST

Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer

RCKTRocket Pharmaceuticals2026-08-03 11:00 EST

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

View all latest news

Rocket Pharmaceuticals

Gene Therapies for Rare Disease Rocket Pharmaceuticals develops gene therapies for rare hematologic and cardiovascular disorders using lentiviral and adeno-associated-virus vectors. Commercial Hematology Franchise KRESLADI is an ex vivo lentiviral gene therapy approved for severe leukocyte adhesion deficiency type I. It represents...

Recent company news

RCKTRocket Pharmaceuticals2026-09-15 11:00 EST

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

RCKTRocket Pharmaceuticals2026-09-03 11:00 EST

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

RCKTRocket Pharmaceuticals2026-08-10 20:00 EST

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

RCKTRocket Pharmaceuticals2026-08-03 11:00 EST

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

RCKTRocket Pharmaceuticals2026-06-12 11:00 EST

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

Stock data

Close
3.50 USD
Market cap
315.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States